


Month 11 [February] | 2021-22 | Operational Performance: Cancer


Worcestershire Acute Hospitals NHS Trust

Responsible Director: Chief Operating Officer | Unvalidated for Feb-22 as 31st March 2022



















Key

- Internal target

irget ial standard COVID Wave

- Operational standard










Month 11 [February] | 2021-22 | Operational Performance: Cancer

Worcestershire Acute Hospitals NHS Trust

Responsible Director: Chief Operating Officer | Unvalidated for Feb-22 as 31st March 2022





Operational Performance: Cancer Benchmarking




National Benchmarking (January 2022)

2WW: The Trust was one of 2 of 13 West Midlands Trust which saw a increase in performance between Dec-21 and Jan-22 This Trust was ranked 12 out of 13; we were 13th the previous month. The peer group performance ranged from 49.94% to 88.88% with a peer group average of 69.92%; declining from 75.70% the previous month. The England average for Jan-22 was 74.99% a -3.7% decrease from 78.64% in Dec-21.

2WW BS: The Trust was one of 8 of 13 West Midlands Trust which saw an increase in performance between Dec-21 and Jan-22 This Trust was ranked 7 out of 13; we were 10th the previous month. The peer group performance ranged from 6.45% to 97.26% with a peer group average of 37.97%; declining from 38.46% the previous month. The England average for Jan-22 was 49.40% a -1.5% decrease from 50.85% in Dec-21.

31 days: The Trust was one of 12 of 13 West Midlands Trust which saw a decrease in performance between Dec-21 and Jan-22 This Trust was ranked 6 out of 13; we were 5th the previous month. The peer group performance ranged from 78.91% to 100.00% with a peer group average of 85.60%; declining from 90.53% the previous month. The England average for Jan-22 was 89.64% a -3.8% decrease from 93.43% in Dec-21.

62 Days: The Trust was one of 13 of 13 West Midlands Trust which saw a Trusts in performance between Dec-21 and Jan-22 This Trust was ranked 4 out of 13; we were 9th the previous month. The peer group performance ranged from 27.70% to 68.42% with a peer group average of 47.78%; declining from 56.22% the previous month. The England average for Jan-22 was 61.79% a -5.2% decrease from 66.95% in Dec-21.





Operational Performance: Planned Care | Waiting Lists



2.4 - Maintain access to all emergency surgery (inc trauma) and triage elective waiting list to prioritise access for those at greatest risk of harm from delay

Electronic R Service (Referra	ERS)	Referral Asso Service (RAS)		Advice & Guidance (A&G) Requests	Total RTT Waiting List	patients on a c pathway waitin weeks for their	Number and percentage of patients on a consultant led pathway waiting less than 18 weeks for their first definitive treatment		patients on a consultant led waiting 40 to 52 pathway waiting less than 18 weeks or more for weeks for their first definitive their first definitive		Number of patients waiting 52+ weeks	Of whom, waiting 78+ weeks	Of whom, waiting 104+ weeks
Total	8,013	Total	5,628	2,586	55,890	25,765	46.10%	5,375	5,888	1,480	466		
Non-2WW	5,262	Non-2WW	4,922	2,500	55,690	25,705	40.10%	5,575	3,000	1,400	400		

What does the data tells us? Referrals

- ERS Referrals: a total of 8,013 electronic referrals were made to the Trust in Feb-22 and is noticeably higher by working day comparing Jan-22 = 365.7 to Feb-22 = 400.7.
- 5,262 were non-2WW referrals so of the total electronic referrals, 35.6% were 2WW cancer.
- **RAS Referrals:** a total of 5,628 RAS referrals were made to the Trust in Feb-22. 4,922 were non-2WW and 79.9% have been outcomed within 14 working days. Of the 706 2WW RAS referrals, 93.6% have been outcomed within 2 working days. 13.6% of RAS referrals were returned to the referrer.
- A&G Requests: 2,586 A&G requests were received in Feb-22 with 94.5% responded to within 2 working days and 97.2% within 5 working days.

Referral To Treatment Time (validated)

- The Trust has seen a 1.7% decrease in the overall wait list size in Feb-22 compared to Jan-22; from 56,846 to 55,890. This is below the H2 target of no more than 58,321 incomplete pathways.
- The number of patients over 18 weeks who have not been seen or treated within 18 weeks has increased to 30,125. This is 373 more patients than the validated Jan-22 snapshot and a 1.2% increase. RTT performance for Feb-22 is validated at 46.10% compared to 47.55% in Jan-22. This remains sustained, significant cause for concern and the 92% waiting times standard cannot be achieved.
- The number of patients waiting over 52 weeks for their first definitive treatment is now the lowest since Aug-21, reducing by 142 to 5,888 patients. Of that cohort, 1,480 patients have been waiting over 78 weeks and 466 over 104 weeks. Of the 104+ week cohort, 293 patients are under the orthodontic specialty with the next highest at 78 (general surgery) and 35 (urology).

	When expected to move to next level of assurance: This is dependent on the programme of restoration of elective activity and reduction of long waiters which are linked to the H2 operational planning requirements (Mar-22).
Previous Assurance Level: 3 (Jan-22)	SRO: Paul Brennan




Month 11 [February] | 2021-22 | Operational Performance: RTT




Responsible Director: Chief Operating Officer | Validated for Feb-22 at 17th March 2022













52+


week waits

5,888













- Internal target

Key

- Operational standard




Operational Performance: RTT Benchmarking




2.4 - Maintain access to all emergency surgery (inc trauma) and triage elective waiting list to prioritise access for those at greatest risk of harm from delay

National Benchmarking (January 2022) | The Trust was one of 9 of 12 West Midlands Trust which saw a decrease in performance between Dec-21 and Jan-22 This Trust was ranked 11 out of 13; no change from the previous month. The peer group performance ranged from 39.53% to 78.41% with a peer group average of 51.63%; improving from 51.38% the previous month. The England average for Jan-22 was 62.80% a -1.0% decrease from 63.80% in Dec-21.

Nationally, there were 311,528 patients waiting 52+ weeks, 6,025 (1.93%) of that cohort were our patients. Nationally, there were 70,645 patients waiting 78+ weeks, 1,571 (2.22%) of that cohort were our patients. Nationally, there were 21,767 patients waiting 104+ weeks, 489 (2.24%) of that cohort were our patients.











Operational Performance: Planned Care | Outpatients and Elective Admissions (2nd SUS Submission)



2.4 - Maintain access to all emergency surgery (inc trauma) and triage elective waiting list to prioritise access for those at greatest risk of harm from delay

Total Outpatient Attendances		Total OP Attendances Face to Face		Total OP Attendances Non Face to Face		% OP Attendances Non Face to Face			Consultant Led Follow Up OP Attendances		Elective IP Day Case		Elective IP Ordinary	
40,836	+4,918	30,193	+7,867	10,643	-2,950	26.1%	10,099	+,1027	12,264	+929	6,215	-124	462	-222

Outpatients - what does the data tell us? (second SUS submission)

- The graphs on slide 20 compare our Feb-22 outpatient attendances to Feb-20 and our H2 activity target. As noted in the top row of this table we achieved the majority of our OP targets. Although we are not undertaking the same volume of appointments in Feb-22 compared to Feb-20, we were at 90% of Feb-20 for total OP activity level overall, 98% for consultant-led first attendances and 83% for consultant-led follow-up attendances.
- The Trust undertook 40,836 outpatient appointments in Feb-22 (consultant and non-consultant led); 4,608 fewer appointments than Feb-20 but +4,918 to our H2 plan.
- In the Feb-22 RTT OP cohort, there are 32,739 RTT patients still waiting for their first appointment, 23.4% of them have been dated and of the total cohort, 2,721 patients have been waiting over 52 weeks. 76% of our longest waiters are undated.
- The top five specialties with the most 52+ week waiters in the outpatient new cohort has not changed and are General Surgery, Orthodontics, Urology, Gynaecology and T&O.
- For Patients awaiting 1st outpatient appointment on pathway, the following have been identified as improvements from Jan-22 to Feb-22.
 - Trauma & Orthopaedics saw a decrease in median wait time of -87.4% from 89 days to 47.5 days, based on a cohort of 1100 patients in the most recent month, compared with a previous cohort size of 1161 patients. Additionally, the mean wait time has decreased by 6.8% from 95.4 days to 89.3 days.
 - Endocrinology saw a decrease in median wait time of -37.1% from 48 days to 35 days, based on a cohort of 355 patients in the most recent month, compared with a previous cohort size of 369 patients.
 - Finally, Rheumatology saw a decrease in median wait time of -35.8% from 110 days to 81 days, based on a cohort of 842 patients in the most recent month, compared with a previous cohort size of 807 patients. Additionally, the mean wait time has decreased by 13.8% from 134.2 days to 117.9 days and the maximum wait time has decreased by 21.1% from 448 days to 370 days.

Planned Admissions - what does the data tell us?

- On the day cancellations shows no significant change since Jun-20.
- Theatre utilisation, at 71.3%, remains just below the mean and is not showing positive improvement. Factoring in allowed downtime, the utilisation increases to 76.3%. Lost utilisation due to late start / early finish showed no significant change at 27.1%
- In Feb-22, the number of day cases decreased and elective ordinary cases increased from Jan-22; both are below the H2 plan. Day cases are 89% of Feb-20 and -124 to our H2 target and elective ordinary are 68%, -222 to H2 target. Our overall elective activity is currently –346 to plan and 87% of Jan-20.
- 43.2% of eligible patients were rebooked within 28 days for their cancelled operation in Feb-22, with 19 of 44 patients being rebooked within the required timeframe.
- The Independent Sector undertook no elective activity in Feb-22 but they did perform 152 diagnostic tests and 112 procedures were undertaken in our Vanguard theatre.

Current Assurance Level: 4 (Feb-22) When expected to move to next level of assurance: This is dependent on the success of the programme of restoration for increasing outpatient appointments and planned admissions for surgery being maintained and the expectation from NSHEI for H2 (Mar-22).		SRO: Paul Brennan	10
		When expected to move to next level of assurance: This is dependent on the success of the programme of restoration for increasing outpatient appointments and planned admissions for surgery being maintained and the expectation from NSHEI for H2 (Mar-22).	



Month 11 [February] | Operational Performance: Theatre Utilisation & Outpatients



Responsible Director: Chief Operating Officer | Validated for Feb-22 as 17th March 2022



Lockdown





Month 11 [February] | 2021-22 | Operational Performance: Outpatients




Responsible Director: Chief Operating Officer | Unvalidated for Jan-22 as 17th March 2022 (Second SUS Submission)

Outpatients | February 2022 attendances compared to 2019/20 and H2 plan









Operational Performance: DM01 Diagnostics | Waiting List and Activity



.4 - Ensure timely access to diagnostics and treatment for all urgent cancer care

					2.4 - Ensure timely a	ccess to diagnostics	and treatment for	all urgent cancer ca	are			NHS Trust
			The total waitin	g list, the num	ber of patients waiti	ng more than 6 wee	ks for a diagnostic	test, and % of pat	ients waiting less	than 6 weeks		
		Trust Total			Radiology			Physiology		Endoscopy		
1	0,234	3,184	68.89%	5,493	1,383	74.82%	3,363	1,275	62.09%	1,378	526	61.83%
What	does the d	ata tell us?						RADIOLO	GY			
DM01	. Waiting Li	st			What have we been doing? What are we goin							
• Th	ne DM01 pe	erformance is val	idated at 68.89% o	f patients	1	I sessions countywi	de, staff permittii	ng.		ls to extend MRI		
l w	aiting less t	han 6 weeks for	their diagnostic te	st, compared		KA WLI sessions			 Identify fund 	ls to extend CT r	nobile	
			n. In summary, this			of CT mobile scann				tment open day		
			ches, with radiolog		Offered 9 ove	rseas Radiographer	posts		 Advertise Co 	nsultant Radiolo	gist posts	
		-	nth from 2,700 to 1								ource Radiograph	ners to utilise
	_	_	decreased by 4.69						capacity on (
	_		10,234 patients, a o	decrease of							MRI, DEXA and U	
		from the previou								orking with WVT	to utilise all avail	lable MRI & CT
			waiting 6+ weeks h						capacity			
1			3,500 for the first						 Continue cor 	ntract with BMI		
			ents waiting over 1		Issues							
Ι,	•	,	rdiography and DE	XA	1	w CT Colon referra	ls, specialised Rac	liographers perfo	rm these which r	ninimises capaci	ty, but we also h	ave sickness in
1	_	58% of our longe			this group of s							
		_	nber of patients wa	_	1	ber of WLI as staff r	_					
			ents from Jan-22, w		1	east 2ww demand f	or MRI- no availal	ble capacity in ho	urs, discussing w	ith Breast how v	ve can utilise OO	H available
	_	_	eased by 1,320 to 1	.,383 (lowest	capacity			20001/1: 0		`		
1		reaches since Dec	,				ENDOS	SCOPY (inc. Gynae	ecology & Urolog	+		-2
		_	the number of pati	_	What have we b	•					going to do nex	
			526 albeit different	patients)	1	for lower GI proc			•		ng a review of a	
		_	e decreased (-71).		1	of self isolation ar	nd PCR testing for	r upper procedur	es remains		vith transformat	
			ies saw an 76 patie		l chancinging							preassessment
		-	number of patients	waiting over	Continuing to	recruit to vacant	_			and clinica	al pathways	
Activi		eased by 379.			 Progressing t 	raining of those n	ewly appointed c	o-ordinators.				
1	,	ostic tosts were	undertaken in Feb-	22		gy waiting lists at I		mproved DMO1	position these			
			sound achieved the		waiting lists v	vill be replaced wit	th GI sessions.					
			't there were still 1		Inhealth prov	ision of endoscopi	sts is improving.					
1		nonth compared		.2/0111016	 Continuing to 	work closely with	radiology to sec	ure addition ERC	P sessions			
1	313 111 11110 11	ionin compared	10 1 20-20.		Issues							

Booking patients is an issue due to covid swab and isolation period – patients declining appointments.

Capacity of booking team to book patients

Issues

Colonoscopy, gastroscopy and flexi sig have all missed their

Finally, echocardiography achieved it's H2 plan, +167 to plan.





Operational Performance: DM01 Diagnostics | Waiting List and Activity



2.4 - Ensure timely access to diagnostics and treatment for all urgent cancer care

	The total waiting list, the number of patients waiting more than 6 weeks for a diagnostic test, and % of patients waiting less than 6 weeks												
	Trust Total Radiology Physiology Endoscopy												
10,234	3,184	68.89%	5,493	1,383	74.82%	3,363	1,275	62.09%	1,378	526	61.83%		
								NEUROPHYS	IOLOGY				





Current Assurance Level: 5 (Feb-22)

Previous assurance level: 5 (Jan-21)

What have we been doing?

- Clinical urgency continues to be reviewed
- Clinics are being booked at KTC and ALX once a week.
- Continue to work mixed shift to allow additional patients to be seen

What are we going to do next?

- WLI approval for a limited amount of clinics, outsourcing staffing these have started
- Identify any opportunities to increase capacity following new IPC guidelines
- 6 day working to help with clinic bookings
- Locum consultant cover to continue reducing EMG w/l

Issues

Staff shortages due to track and trace

CARDIOLOGY - ECHO

What have we been doing?

- Consultant team have started clinical validation of the waiting list – hopeful completion end of Feb 22
- Echo service has move to KTC to allow for collaborative working across the trust – there have been some issues due to sickness but this is resolving
- WLIs have place on weekends to help backlogs and will continue throughout this project
- Plans to recover most of the waiting list by April 22 but will be heavily dependent on staffing levels

What are we going to do next?

- Continuation of lists through Kidderminster until 04/04/22 where workloads will return to site
- Completion of the clinical validation – early estimations are 15-25% reduction from this
- Continued WLI clinics where possible

Issues

Staff shortages due to track and trace and high vacancy rate

When expected to move to next level of assurance: This is dependent on the on-going management of Covid and the reduction in emergency activity which will result in increasing our hospital and CDC capacity for routine diagnostic activity.


SRO: Paul Brennan



Month 11 [February] 2021-22 | Operational Performance: DM01 Diagnostics

Worcestershire Acute Hospitals NHS Trust

Responsible Director: Chief Operating Officer | Validated for Feb-22 as 17th March 2022



These graphs represent annual planning restoration modalities only. All other physiology tests, DEXA and cystoscopy were not included in the request from NHSEI.




Operational Performance: Diagnostics (DM01) Benchmarking



National Benchmarking (January 2022) | The Trust was one of 3 of 13 West Midlands Trust which saw a decrease in performance between Dec-21 and Jan-22 This Trust was ranked 12 out of 13; we were 10th the previous month. The peer group performance ranged from 3.71% to 55.29% with a peer group average of 33.59%; declining from 32.44% the previous month. The England average for Jan-22 was 30.00% a 1.0% decrease from 29.00% in Dec-21.

In Jan-22, there were 152,028 patients recorded as waiting 13+ weeks for their diagnostic test; 1,916 (1.26%) of these patients were from our Trust.





Previous Assurance Level: 5 (Jan-21)

Operational Performance: Stroke



	% of patients spending 90% of time on a Stroke Ward A&E) to a Stroke Ward within 4 hours				rho had a CT within tes of arrival	% patients see within 2	SSNAP Q3 21-22 Oct-21 to Dec-21				
71.70%	Е	32.08%	Е	45.28%	В	89.11%	N/A	Score	72.0	Grade	В
meant an im 64.6 to 72.0. SSNAP Domain 1 Scanning 2 Stroke unit 3 Thrombolysis 4 Specialist Assessme 5 Occupational therage 6 Physiotherapy 7 Speech and Language 8 MDT working 9 Standards by discha 10 Discharge processe Combined Total Key Indica Case ascertainment band Audit compliance band SSNAP store Team-centred SSNAP level (after Comparing til their grade a domains imp overall score Only one of t cause concer seen in the T	nts y te therapy adjustments) the 10 domains to nd 8 maintained roved their overa reduce. the four main stron which was dire IA clinic within 24	oke metrics show perfo	change in score from 2021/22 Q1 Q2 Q3 C C C E E E E E E E C B B A A A B A A B C C D C B A B A D A A 60.0 68.0 72 C C B 80-85% 90%+ 90%+ 54.2 64.5 72 D C B hows that 2 improved ous quarter. Also 7 the same and 2 saw their remance that is special rd. The target for being this month.	inpatient beds ou flow issues. The the Health & Care Traction across the pathwood response. Limited (ED and MAU). A second time with Equivalent of 1W 90% Stay on Stroprimarily). To not unit. TIA Patients Seen clinics have record day which is allow target of 80% (ac Specialty Review consultant. The specialist in-hou commenced (7th Ethrombolysis dec ceased at presen on goodwill at pr	b improve? d Within 4 Hours: This is chut of county along with the eam are working with Heaust beds. A joint post (strokay and facilitate flow. Exard stroke consultants continus ubstantive consultant has a closing date of 4 th April. TE mutual aid from UHNM ke Ward: Issues described te, the team provides time. Within 24 Hours: All referented at weekend (2 sleving us to maintain achieve hieved last 5 months) Within 30 Minutes: All referented are given a swallow february 2022) which will sision-making was trialled fit due to resource availabilitiesent so is dependent on starces are successively are	receipt of timely refer- sith & Care Trust to ide te co-ordinator) is out- inples of inappropriate ues to be an issue in te to been appointed (com A second post, purely in place, along with 1 above impact on this I ly therapy and stroke a rrals now triaged appro- tots per day) During we ement of TIA standard. errals to stroke team free dedicated to ensuring to screen within 24 hrs a upport improvements or the month of Febru- ty. Long term aim for uccessful further recru-	rals from ED due to be ntify appropriate Reh to advert which will propre-alerts have been erms of timely review mences May 22). A jo WAHT has also gone cagency locum and lim (PI (access to rehab be assessment wherever opriately by Stroke coreckdays, TIA clinic cap. We are improving perom ED are reviewed in all stroke patients propriately by Stroke coreckdays, Tia clinic cap. We are improving perom ED are reviewed in this metric. A local ary. The impact of this this to be permanently itiment and input from	eing overwheeling overwheeling overwheeling overwheeling in Electronic education of the patient in the patient	elmed and to improve for the composition of states and still a display and still a dis	the associated low out to the roke capacity awaiting a and new referrent to advert for those on State rejections. If by 2 slots pead achieving consultation used by stroke ow to support sed and has rethis is being	d lee / rals for a ate. TIA er g the with e
Current Assurance	Level: 5 (Feb-22)				e to next level of assurance: Monts in the SSNAP score / grade			ing the main st	roke metrics	and demonstra	able

SRO: Paul Brennan




Month 10 [January] | 2021-22 | Operational Performance: Stroke


Responsible Director: Chief Operating Officer | Validated for Jan-22 as 28th March 2022

























Please note: These SPC charts have been re-based to evidence if any changes in performance, post the initial COVID-19 high peak, are now common or special cause variation.







Quality and Safety





Summary Performance Table | Month 11 [February] 2021-22

Quality	and Safety Metrics	Latest Month	Measure	Target	Performance	Assurance	Mean	Lower process limit	Upper process Limit
	C-Diff	Feb-22	4	4	@/he	2	5	0	10
eventic	Ecoli	Feb-22	4	4	⊕	2	4	0	9
Infection Prevention	MSSA	Feb-22	1	0	@/ha	2	2	0	6
Infe	MRSA	Feb-22	0	0	⊕	2	0	0	1
	Acquired Pressure Serious Incidents	Feb-22	0	-	⊕	2	0	0	2
	er 1,000 bed days ausing harm	Feb-22	0	0.04	@/\ps	2	0	0	0
	dicine incidents ausing harm	Feb-22	2.88	11.71	√	2	3	0	10
iene	Hand Hygiene Audit Participation	Feb-22	90.99	100	a√\so	2	91	79	103
Hand Hygiene	Hand Hygiene Compliance to practice	Feb-22	99.69	98	H~		99	99	100
VTE A	ssessment Rate	Feb-22	94.3	95	∞	2	96	94	98
is	Sepsis Screening compliance	Jan-22	82.91	95	@/he	2	83	71	95
Sepsis	Sepsis 6 bundle compliance	Jan-22	53.47	95	(H.	(F	53	28	77
#NOF ti	me to theatre <=36 hrs	Feb-22	76.6	85	⊕	2	77	58	97
	rtality Reviews bleted <=30 days	Nov-20	35.5	-	(n/he)	2	43	20	67
HSMR	12 month rolling average	Jun-21	95.61	-	⊕	2	104	101	107
Complai	nts responses <=25 days	Feb-22	68.57	80	@/bs)	2	77	46	108
wed	ICE viewed reports [pathology]	Jan-22	92	-	€-		95	94	97
Ice viewed reports	ICE viewed reports [radiology]	Jan-22	90.85	-	(H.~)		86	82	90

Quality and Safety Metrics	Latest Month	Measure	Target	Performance	Assurance	Mean	Lower process limit	Upper process Limit
FFT A&E Response	Feb-22	17.97	20	٩٨٥	?	17.30	12	23
FFT A&E Recommended	Feb-22	74.49	95	⊕	E	82.31	75	89
FFT Inpatient Response	Feb-22	29.71	30	0 ₀ /\u00e40	?	31.69	24	39
FFT Inpatient Recommended	Feb-22	95.78	95	4/4	2	95.68	94	97
FFT Maternity Response	Feb-22	1.94	30	(T-)	?	18.89	4	34
FFT Maternity Recommended	Feb-22	100	95	•/•	?	93.47	73	113
FFT Outpatients Response	Feb-22	10.62	10	0√ 00	?	10.46	7	14
FT Outpatients Recommended	Feb-22	92.11	95	√ /⊷	2	93.32	92	95



Integrated Quality Performance Report - Headlines



Quality Performance	Comments (All metrics on this slide have additional Improvement Statements later in this report)
Infection Control	 The number of <i>C.difficile</i> infections in Feb-22 decreased to 4. There is currently 1 ward outbreak of C.difficile which is in the monitoring phase. Last positive case 03-12-21. E-Coli BSI has now breached our Trust internal target of no more than 30 cases for the financial year 2021/2022. However, we are achieving the national trajectory. MSSA BSI has breached the Trust target of no more than 10 cases for the financial year 2021/2022. There is no national target. MRSA BSI, Klebsiella species and Pseudomonas aeruginosa are achieving the year to date trajectories. Hand Hygiene Practice Compliance rate continues to perform above the 98% target, with 99% being exceeded for the last 25 months. Antimicrobial Stewardship overall compliance for Feb-22 remained stable at 87.98% and missed the target of 90%. Patients on Antibiotics in line with guidance or based on specialist advice in Feb-22 was 91.31% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. 8 new COVID outbreaks were declared in Feb-22. There are currently 7 ongoing outbreaks and a further 5 in the monitoring phase.
SEPSIS 6	 Our sepsis 6 screening performance increased in Jan-22. We will not on average hit the target, but not consistently, it may succeed due to random variation. We have achieved the target again for antibiotics being provided within one hour. This has been achieved for 11 out of the last 12 months.
VTE Assessments	 This is the first month since March 2019, where we have not achieved the Trust target of 95%. However, W&C are now entering VTE assessments via Badgernet which have not yet been factored into the Trust results. Excluding all W&C data from Feb-22 results, our compliance is 97.42%
ICE Reporting	 The Target of 95% for viewing Radiology Reports on ICE has not been achieved in the past 22 months (range 80.56% to 91.37%). The Target of 95% for viewing Pathology Reports on ICE was missed for the seventh month running.
Fractured Neck of Femur	 There were 77 #NOF admissions in February. Our performance within 36 hours was 76.6% and the average time to theatre was 27.6 hours. There were a total of 1842 breaches in January – 6% were due to bed issues and 50% were due to theatre capacity.



Integrated Quality Performance Report - Headlines



Quality Performance	Comments
Friends & Family Test	 The recommended rate for Inpatients has achieved target for 12 months in a row. The response rate has fell just under 30%. The recommended rate for Maternity in Feb-22 has shown special cause variation. However, the response rate for Jan-22 was only 1.94%, which equates overall to 10 responses. The recommended rate for Outpatients has shown special cause variation since Jun-21. Our response rate for Feb-22 achieved the target of 10% and is showing normal variation. The recommended rate for A&E will not meet the target without intervention. Performance has shown special cause variation since Jun-21. Our A&E response rate in Feb-22 was 17.97% and is showing normal variation.
Complaints	• Complaints responded to within 25 working days is showing normal variation. The target was missed at 68.57%. The Divisions which did not achieve the 80% target in Feb-22 were Surgery (36%) and Womens & Childrens (40%).
Hospital Acquired Pressure Ulcers (HAPU)	 There were zero Serious Incident HAPU's in Feb-22, and the metric is achieving the year to date trajectory. There were 21 HAPUs in Feb-22, which exceeded the in-month target by 1. The total of 185 HAPUs year to date is well under the year to date trajectory of 226. There were 61 Cat 3, 4 or Unstageable pressure ulcers on admission in Feb-22 which is showing normal variation.
Falls	 The total number of falls for Feb-22 was 94 which fell below the in-month target. We are currently 14 falls over our year to date trajectory. The number of falls per 1,000 bed days decreased in Feb-22 to 4.66 and remains below the national benchmark of 6.63. There were no SI falls in Feb-22 and the total for the financial year is 5, which is 1 away from breaching the Trust target. However, 1 fall remains under investigation and 1 has been requested for downgrade.
Never Events	• In total, there have been 9 Never Events in 2021/22. Two thirds of those occurred in SCSD areas.
MSA Breaches	• In Feb-22, we had a total of 42 MSA breaches (63 last month).



2.1 Care that is Safe - Infection Prevention and Control

Worcestershire Acute Hospitals

Embed our current infection prevention and control policies and practices | Full compliance with our Kev Standards to Prevent **C-Diff** E-Coli **MSSA Pseudomonas MRSA** Klebsiella species * Trust target of 30 * Trust target of 10 * National target of 61 aeruginosa Feb Year to date Feb Year to date Feb Year to date Feh Year to date actual Feb Year to date Feb Year to date actual vs target actual vs actual / year actual vs actual / year to actual vs actual / year to actual vs / year to date actual / year to actual vs actual / year to date target date target to date target target target date target target target target date target target 4/5 82/56 4/3 33/27 1/0 21/10

What does the data tell us?

- The number of C.difficile infections in Feb-22 decreased to 4. There is currently 1 ward outbreak of C.difficile which is in the monitoring phase. Last positive case 03-12-21.
- E-Coli BSI has now breached our Trust internal target of no more than 30 cases for the financial year 2021/2022. However, we are achieving the national trajectory.
- MSSA BSI has breached the Trust target of no more than 10 cases for the financial year 2021/2022. There is no national target.
- MRSA BSI, *Klebsiella species* and *Pseudomonas aeruginosa* are achieving the year to date trajectories.
- The Hand Hygiene audit participation rate has improved since Apr-21. However, we have not achieved 100% participation since Jan-20.
- Hand Hygiene Practice Compliance rate continues to perform above the 98% target, with 99% being exceeded for the last 25 months. This metric will reliably achieve the target.
- 8 new COVID outbreaks were declared in Feb-22. There are currently 7 ongoing outbreaks and a further 5 in the monitoring phase.
- All of the high impact intervention audits in Feb-22 had an overall compliance above 95%. The two audits which had the lowest compliance were central venous access devices - Insertion Phase (97.8%) and peripheral vascular access devices - Ongoing Care (98.8%).

- The wider context with C.difficile is that the overall community numbers have risen
 across the system and more widely. Overprescribing of antibiotics in the community
 during the pandemic due to the switch to remote consultation has been reported to
 be a driving factor in this.
- We have identified a specific issue relating to the removal of radiator covers for deep cleaning on the WRH site. A deep cleaning programme has now commenced.
- The Staphylococcus aureus BSI Quality Improvement Steering Group is making some progress, though operational and staffing pressures have resulted in significant delays. A paper setting out more detail was brought to CGG, TME and QGC in January 22. The team are focussed on implementation of the PVD packs, a new PVD monitoring form, and are planning an awareness campaign on these issues as well as the IVAD guidelines.
- Progress with the enhanced C.difficile action plan has been significantly affected by
 operational and staffing pressures. These have resulted in significant delays to
 achievement of actions. A paper setting out more detail was brought to CGG, TME
 and QGC in January 22. A series of Scrutiny & Learning Meetings has been held to
 catch-up on delayed reviews to ensure learning is identified and shared.
- A location for the bed and trolley deep cleaning facility has been identified on both sites. Work is progressing to operationalise the Alex site facility. The WRH site location will need capital works to enable it to progress, and that is presently being worked on.

 $\label{lem:assurance} Assurance \ level - Level \ 6 \ COVID-19 \ / \ Level \ 4 \ for non-Covid \ (Nov-21) \\ Reason: Current performance in relation to C. difficle and MSSA BSI$

When expected to move to next level of assurance for non Covid:

This will be next reviewed in April 22, when quarter 4 performance can be assessed.

Previous assurance level (Oct-21) –Level 6 COVID-19 / Level 4 for non-Covid SRO: Pa

SRO: Paula Gardner(CNO)



Infection Prevention and Control Benchmarking



Source: Fingertips (up to December 2021)

C. Difficile – Out of 24 Acute Trusts in the Midlands, our Trust sits the 4th highest for hospital onset-healthcare associated C. difficile infections. Our rate stands at 23.3 cases per 100,000 bed days, which is above both the overall England and Midlands rate. Wye Valley is the highest Trust and has a rate of 49 cases per 100k bed days. **E.Coli** – Out of the 24 Acute Trusts in the Midlands, our Trust sits the 7th best. Our rate stands at 14.8 cases per 100,000 bed days, which is below the overall England and Midlands rate.

MSSA – Out of 24 Acute Trusts in the Midlands, our Trust sits the 10th best. Our rate stands at 8 cases per 100,000 bed days, which is below both the overall England and Midlands rate.

MRSA – Out of the 24 Acute Trusts in the Midlands, our Trust sits the 13th highest. Our rate stands at 1 case per 100,000 bed days, which is below both the overall England and Midlands rate.

C. Difficile infection counts and 12-month rolling rates of hospital onset-healthcare associated cases Dec-21

Area	Count	Per 100,000 bed days
England	5,754	18,5
Midlands NHS Region	968	16.6
Worcestershire Acute Hospitals	55	23.3

MSSA bacteraemia cases counts and 12-month rolling rates of hospital-onset | Dec-21

Area	Count	Per 100,000 bed days
England	3,771	12.1
Midlands NHS Region	610	10.4
Worcestershire Acute Hospitals	19	8.0

E. Coli hospital-onset cases counts and 12-month rolling rates | Dec-21

Area	Count	Per 100,000 bed days
England	7,063	22.8
Midlands NHS Region	1,248	21.4
Worcestershire Acute Hospitals	35	14.8

MRSA cases counts and 12-month rolling rates of hospital-onset | Dec-21


Area	Count	Per 100,000 bed days
England	285	0.9
Midlands NHS Region	40	0.7
Worcestershire Acute Hospitals	1	0.4



Month 11 [February] | 2021-22 Quality & Safety - Care that is Safe

Worcestershire Acute Hospitals NHS Trust

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for Feb-22 as 9th March 2022












Month 11 [February] | 2021-22 Quality & Safety - Care that is Safe


Worcestershire Acute Hospitals NHS Trust

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for Feb-22 as 9th March 2022

Hand Hygiene Audit Participation (%)













Lockdown Period COVID Wave



2.1 Care that is Safe – Antimicrobial Stewardship



	ompliance et 90%)	e Antibiotics in line with guidance (Target 90%)		Antibiotics reviewed within 72 hours (Target 90%)	
Feb-22	Jan-22	Feb-22	Jan-22	Feb-22	Jan-22
87.98%	88.13%	91.31%	91.36%	91.32%	88.04%

Mat will we be doing? A total of 337 audits were submitted in Feb-22, compared to 329 in Jan-22. Antimicrobial Stewardship overall compliance for Feb-22 remained stable at 87.98% and missed the target of 90%. Patients on Antibiotics in line with guidance or based on specialist advice in Feb-22 was 91.31% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed within 72 hours in Feb-22 was 91.32% and achieved the target of 90%. Patients on Antibiotics reviewed on April 20, when quarter 4 performance can be assessed. When expected to mo	87.98%	88.13%	91.31%	91.36%	88.04%				
Assurance level – Level 6 COVID-19 / Level 4 for non-Covid (Nov-21) - Antimicrobial stewardship level of assurance is 5 as assessed by ASG on 24/02/2022. Reason: Current performance in relation to C.difficile and MSSA BSI Watch and Reserve categories. • AMR CQUIN focussing on improving diagnosis and treatment of UTI in over 16s • Focusing on accurate completion of allergy documentation to include symptoms of allergic reaction • Focusing on learning from C diff case reviews where antibiotics may be implicated • AMS QI project underway across Urgent Care division with a focus on identifying and addressing AMS barriers through behaviour change orientated interventions. When expected to move to next level of assurance for non Covid: This will be next reviewed in April 22, when quarter 4 performance can be assessed. Previous assurance level (Oct-21) – Level 6 COVID-19 / Level 4 for non-Covid SRO: Paula Gardner(CNO)	 A total of 337 audits we Antimicrobial Stewards 87.98% and missed the Patients on Antibiotics 	ere submitted in Feb-22, con thip overall compliance for Fo target of 90%. in line with guidance or base	eb-22 remained stable at	Divisional AMS clinical less Focus monthly audits will and a Antimicrobial Stewardsh carbapenems (current userbapenems (current userbapenems et al.) Divisions will be developed Prevalence Survey resultantimicrobial prescribing	ith their junior doctors nip Group will continue se now sits below base ning action plans to imp ts (a snapshot audit un g standards)	to monitor the use of e-line pre-Covid levels) prove their Quarterly Point dertaken on one day against			
assurance is 5 as assessed by ASG on 24/02/2022. Reason: Current performance in relation to C.difficile and MSSA BSI Previous assurance level (Oct-21) – Level 6 COVID-19 / Level 4 for non-Covid SRO: Paula Gardner(CNO)			Feb-22 was 91.32% and	 Watch and Reserve cate AMR CQUIN focussing o Focusing on accurate co of allergic reaction Focusing on learning fro implicated AMS QI project underwa identifying and addressing 	 Watch and Reserve categories. AMR CQUIN focussing on improving diagnosis and treatment of UTI in over 16s Focusing on accurate completion of allergy documentation to include symptoms of allergic reaction Focusing on learning from C diff case reviews where antibiotics may be implicated AMS QI project underway across Urgent Care division with a focus on identifying and addressing AMS barriers through behaviour change orientated 				
	assurance is 5 as assessed by ASG	on 24/02/2022.	- Antimicrobial stewardship level o		·				
	Previous assurance level (Oct-21)	Level 6 COVID-19 / Level 4 for no	n-Covid	SRO: Paula Gardner(CNO)	SRO: Paula Gardner(CNO)				



2.1 Care that is Safe – Falls



Total Inpatient Falls	Inpatient Falls resulting in Serious Harm	Falls per 1,000 bed days	Falls per 1,000 bed days (serious harm)	
Year to date: Actual / Year to date target	Year to date: Actual / Year to date target	Feb-22	Feb-22	
1146/ 1132 (Target – 1235)	5 / 5 (Target – 6)	4.61 (National Target – 6.63)	0	
 We are currently 14 falls over our yea The number of falls per 1,000 bed day below the national benchmark of 6.63 	vs decreased in Feb-22 to 4.66 and remair B. The total for the financial year is 5, which is B. However, 1 fall remains under	 Falls assessment implemented in all Ass Creation of interim trust falls training delayed (ceased January 2021) Ad-hoc virtual training for wards/depart Purchase of Ramblegard falls prevented 	artments with increased prevalence ative technology for 2 wards ices workshops ongoing with a focus on	
Assurance levels (Quarter 3); Falls – Level 5		When expected to move to next level of assurance Quarter 4		
Previous assurance level (Quarter 1); Falls – Level 6		SRO: Paula Gardner(CNO)		




Month 11 [February] | 2021-22 Quality & Safety - Care that is Effective


Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for Feb-22 as 9th March 2022
























Previous assurance level – Level 5 (Oct-21)

2.2 Care that is Effective – Improve Delivery in Respect of the SEPIS Six Bundle



 What does the data tell us? Our performance against the sepsis bundle being given within 1 hour has decreased in Jan-22. We will not meet the target without intervention. Our sepsis 6 screening performance increased in Jan-22. We will not on average hit the target, but not consistently, it may succeed due to random variation. We have achieved the target again for antibiotics being provided within one hour. This has been achieved for 11 out of the last 12 months. Between Apr-21 and Oct-21, there were 775 patients that had a diagnosis of sepsis, of which 176 (23%) unfortunately died. Our Crude in-hospital death rate is 14.6%, which is one of the lowest rates seen across the Trusts within the Midlands. However, our out-of-hospital death rate is 8.1%, which is the What improvements will we make? Update to Sepsis Patient Pathway documentation (Version 4). This will allow documentation of screening of 'Suspected Sepsis' patients and the 'face to face' review on the same form to avoid duplication in the medical/nursing notes. Hopefully we will also improve the 'team approach' to Sepsis management, however it will take a few months for the changes to be recognised in the data. A retrospective audit will take place to determine the causes of out of hospital deaths and whe there is any cause for concern. From April 2022 all deaths, including those in community will have mortality review – these wind help to identify concerns in real time. Development of 'real-time' audit processes to improve patient management when it matters in Specialty Medicine audit data corresponds appropriately with Trust-wide audit which it will register. 	Sepsis six bundle completed in one hour (Target 90%)	Sepsis screening Compliance Audit (Target 90%)	% Antibiotics provided within one hour (Target 90%)	Urine	Oxygen	IV Fluid Bolus	Lactate	Blood Cultures
 Our performance against the sepsis bundle being given within 1 hour has decreased in Jan-22. We will not meet the target without intervention. Our sepsis 6 screening performance increased in Jan-22. We will not on average hit the target, but not consistently, it may succeed due to random variation. We have achieved the target again for antibiotics being provided within one hour. This has been achieved for 11 out of the last 12 months. Between Apr-21 and Oct-21, there were 775 patients that had a diagnosis of sepsis, of which 176 (23%) unfortunately died. Our Crude in-hospital death rate is 14.6%, which is one of the lowest rates seen across the Trusts within the Midlands. However, our out-of-hospital death rate is 8.1%, which is the 	53.47%	82.91%	90.1%	69.31%	98.02%	95.05%	83.17%	85.15%
	 What does the data tell us? Our performance against the sepsis bundle being given within 1 hour has decreased in Jan-22. We will not meet the target without intervention. Our sepsis 6 screening performance increased in Jan-22. We will not on average hit the target, but not consistently, it may succeed due to random variation. We have achieved the target again for antibiotics being provided within one hour. This has been achieved for 11 out of the last 12 months. Between Apr-21 and Oct-21, there were 775 patients that had a diagnosis of sepsis, of which 176 (23%) unfortunately died. Our Crude in-hospital death rate is 14.6%, which is one of the lowest rates seen across the Trusts within the Midlands. However, our out-of -hospital death rate is 8.1%, which is the 6th highest rate. Our average LOS for sepsis patients between the same period was 8.59 days. We are below the Midlands total of 9.52 days 				s Patient Pathway do spected Sepsis' patient emedical/nursing nonent, however it will the audit will take place the for concern. If all deaths, including concerns in real times of 'real-time' audit profine audit data corresponding audit Medicine will specialty Medicine will specialty Medicine will specialty medicine will specialty Medicine will special sp	nts and the 'face to face to determine the cause those in community we compare to face	ce' review on the sam also improve the 'tea the changes to be red es of out of hospital devill have mortality revient management whith Trust-wide audit versions.	ne form to avoid am approach' to cognised in the leaths and whether liew – these will en it matters most which it will replace


SRO: Christine Blanshard (CMO)




Month 11 [February] | 2021-22 Quality & Safety - Care that is Effective

Worcestershire Acute Hospitals NHS Trust

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for Feb-22 as 9th March 2022








Sepsis Screening Antibiotics Compliance (audit)

90.1%



Special Special Common Cause Concern High Low High Low





- Lockdown Period



2.2 Care that is Effective – VTE assessment and VTE assessments within 24 hours



VTE assessmen	t on admission to hospital
February 2022	Target
94.30%	95%
 What does the data tell us? This is the first month since March 2019, where we have not achieved the Trust target of 95%. However, W&C are now entering VTE assessments via Badgernet which have not yet been factored into the Trust results. Excluding all W&C data from Feb-22 results, our compliance is 97.42% 	 What improvements will we make? Trust Thrombosis committee are continuing to monitor actions following the completion of VTE assessments to ensure learning and improved practice HAT's are routinely discussed at the Trust Thrombosis committee and any learning shared; none have been identified The Information Team are working with Badgernet to build the table structure to ensure data can be pulled across into the Data Warehouse. Regular spot audits to look at compliance with the assessment, both in terms of prescription & delivery. This will be fed back quarterly by each division.
Assurance Level: 7	When expected to move to next level of assurance : N/A SRO: Christine Blanshard (CMO)




Month 11 [February] | 2021-22 Quality & Safety - Care that is Safe

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for Feb-22 as 9th March 2022







Please note that % axis does not start at zero.







- Lockdown Period



2.2 Care that is effective - ICE Reporting



% Radiology reports viewed - ICE	% Radiology reports filed – ICE	% Pathology reports viewed - ICE		
90.85% - Jan 2022 (90.52% - Dec 2021)	72.82% (72.56%)	92.00% 67.33% (92.44%) (65.80%)		
 What does the data tell us? The Target of 95% for viewing Radiolog the past 22 months (range 80.56% to 9) The Target of 95% for viewing Patholog seventh month running in Jan-22 at 92 Radiology reports filed on ICE has remonths. Pathology reports filed on ICE has remonths. 	gy Reports on ICE was missed for the 2.00%. ained above 70% for eight consecutive	 What will we be doing? On the 24th February 2022, the Digital Team bulk filed all Pathology and Radiology reports up to and including the 31st December 2020. Reports with an abnormal flag were not included and require clinical review and filing manually. Statutory requirements for viewing & filing of reports to be reviewed Filing prompt has gone live to ensure when viewing a result it is then filed appropriately Auto filing of all GP results will go live in the next few weeks 		
Assurance level – Level 5 (Feb-22)		When expected to move to next level of assurance: Following implementation of the above measures		
Previous assurance level: Level 5 (Oct-21	.)	SRO: Christine Blanshard (CMO)		





Month 11 [February] | 2021-22 Quality & Safety - Care that is Effective


Worcestershire Acute Hospitals NHS Trust

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for Feb-22 as 9th March 2022









Please note that % axis does not start at zero









2.2 Care that is Effective – Fractured Neck of Femur (#NOF)



#NOF – Time to Theatre <= 36 Hours	#NOF – Time to Theatre <= 36 Hours Excluding Unfit Patients
76.6% (Feb 2022) 49.4% (Jan 2022)	81.94% (Feb 2022) 52.6% (Jan 2022)
 What does the data tell us? We have seen an improvement with #NOF compliance in Feb-22, however the SPC is still showing special cause concern due to the run of months below the mean. There were 77 #NOF admissions in February. The #NOF target of 85% has not been achieved for 23 months. There were a total of 18 breaches in February (42 in January); 6% of the breaches were due to bed issues and 50% were due to theatre capacity. 33% of our breaches were due to the patient being medically unfit/ non-operative management. Other reasons include further imaging of fracture site required and transfer to another hospital. The average time to theatre was 27.6 hours (39.7 in January). Our Crude Death Rate for #NOF is 14.5% and is the second highest Trust in the Midlands. Our average LOS is 10.5 days, which is the lowest Trust in the 	 What will we be doing? Centralising all Inpatient Trauma to WRH site from 13th November as a result increasing Trauma theatre capacity by one 4 hour session per day. Changing consultant on-call pattern to ensure there is always a hip surgeon available to operate. Increasing weekend Trauma Theatre from 2 sessions to 4 where staffing allows in the short term. Long term business case required to staff additional 2 sessions at weekends. Escalating the need for ring fenced #NoF beds in the community (previously the department had access to 9 beds) this will ensure constant flow.
Midlands. Current assurance level: 5 (Nov-21)	When expected to move to next level of assurance: Mar-22
Previous assurance level: 5 (Oct-21)	SRO: Christine Blanshard (CMO)




Month 11 [February] | 2021-22 Quality & Safety - Care that is Effective

Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for Feb-22 as 9th March 2022

















2.3 Care that is a positive experience – Friends and Family



FFT Inpatient	Recommended	FFT Outpatient Recommended		utpatient Recommended FFT AE Recommended		FFT Maternity Recommended	
Feb-22	Target	Feb-22	Target	Feb-22	Target	Feb-22	Target
95.78%	95%	92.11%	95%	74.49%	95%	100%	95%

What does the data tell us?

- The recommended rate for Inpatients has achieved target for 12 months in a row. The response rate has fell just under 30%.
- The recommended rate for Maternity in Feb-22 has shown special cause variation. However, the response rate for Jan-22 was only 1.94%, which equates overall to 10 responses.
- The recommended rate for Outpatients has shown special cause variation since Jun-21. Our response rate for Feb-22 achieved the target of 10% and is showing normal variation.
- The recommended rate for A&E will not meet the target without intervention. Performance has shown special cause variation since Jun-21. Our A&E response rate in Feb-22 was 17.97% and is showing normal variation.

What improvements will we make?

- Divisions report quarterly to the Patient, Carer and Public Engagement steering group presenting patient experience data and actions from feedback.
- The Patient Experience Lead Nurse is currently reviewing FFT cards available for Xerox to ensure they are up to date ahead of reintroducing cards once this is complete a paper can proceed to Bronze Command for agreement to reintroduce cards ensuring wards can order up to date cards.
- Maternity have introduced FFT returns on Badgernet areas are continuing to use iPads for collection while this is trialed. The Informatics team are exploring how the data can be pulled from Badgernet to support feedback returns without cost implication alongside FFT providers being explored (Business Case generation).
- Badgernet enables increased focus on free text comments which is intended to support timely Quality
 Improvement in the Division. Progress is underway to support Ward Managers to display the feedback.
- A carousel "tender competition" with potential suppliers has taken place to inform the Business Case for a provider to work with the Trust on FFT collection and presentation of data to better understand how and where the Patient Experience is improving, to increase the ability to really understand and learn from free-text comments, provide deeper analysis and continuously deliver on our ability to listen learn and improve this is intended to support an increased response rate and a thorough understanding of this improvement. This approach has demonstrated significant improvements in other Trusts.. This process has been coordinated by the Digital Team with support from the Head of Patient, Carer and Public Engagement. Suppliers have been assessed and a Business Case is in development; this is expected to be presented for a decision in June 2022.
- Recommended rates continue to be impacted by family and friends not being able to visit loved ones in hospital.
 National Guidance from NHS England has been received in March 2022 giving clear guidance on Visiting Expectations the Trust position will be drafted and presented to the Command and Control Meetings for comments, agreement and roll out.

Assurance level – Level 5 (Nov-21)

When expected to move to next level of assurance: Q4 2021/22

Previous assurance level – Level 5 (Oct-21)

SRO: Paula Gardner (CNO)




Month 11 [February] | 2021-22 Quality & Safety - Care that is a positive experience for patients/ carers





Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for Feb-22 as 9th March 2022



























2.3 Care that is a positive experience – Complaints



Complaints Responded to Within 25 Days						
Feb-22	Target					
68.57%	80%					

What does the data tell us?

- Complaints responded to within 25 working days is showing normal variation. The target was missed at 68.57%. The Divisions which did not achieve the 80% target in Feb-22 were Surgery (36%) and Womens & Childrens (40%).
- Although the overall percentage is reduced from December and January, it shows that
 Divisional Teams are continuing to work through and close their backlogs of breached
 cases and can be viewed as positive, and a step towards returning performance to above
 target.
- A larger number of complaints were received in Q2 & Q3, equal to and sometimes in
 excess of pre-pandemic levels; this has continued into Q4 and has affected the ability of
 some Divisional Teams to manage the caseload as effectively, whilst dealing with ongoing
 Covid pressures and additional winter pressures.
- The sustained increase in new cases being received has led to a reduction in performance percentage, however overall annual performance is still above target as of 14.03.2022.
- The increase in complaints numbers continues to be reflected countywide, and across the West Midlands region.

What improvements will we make?

- The Complaints Team are currently piloting a process in Urgent Care and Women and Children's Divisions to agree "terms of reference" for complaints at the start of the process in order to produce template responses which will reduce the work for Divisional Teams in completing drafts.
- The impact of this pilot on timeliness of response drafts and quality (measured by reopened figure) will be carried out in Q1 2022-2023.
- All Corporate cases will be reviewed at the earliest opportunity by the Complaints Manager to aim for early resolution
- The total number of overdue complaints has remained reduced through February 2022, demonstrating that the backlog continues to be addressed. When breach cases are resolved, this leads to a reduced performance percentage – improvements will take time to be evident while the overdue cases are cleared; the performance KPI is currently at 85% for March as of 14/03/2022, demonstrating improvement.

Current Assurance Level – Level 5 When expected to move to next level of assurance: End of Q4.

Previous Assurance Level – N/A SRO: Paula Gardner (CNO)




Month 11 [February] | 2021-22 Quality & Safety - Care that is Effective


Responsible Director: Chief Nursing Officer, Chief Medical Officer | Validated for Feb-22 as 9th March 2022




























Maternity



Previous Assurance Level: 5 (Jan-22)

Month 11 [February] 2021-22 Maternity



term b	on of full- abies to tal care	Neonatal Deaths (>24 ⁺⁰ weeks gestation)	Stillbirths	Maternal Deaths	Pre-term births		Home	Home births		Booked before 12+6 weeks		Babies
4.6%	19	2	1	0	7.8%	29	0.8%	3	74.2%	492	364	372
Booki concervies The hochoic centr Sadly mate In resiletter have cause "concand in Repo	ern; the prowed. nomebirth re and the ace/ambulanthere was rnal deaths sponse to the published been amere variation letern". The enstrumentarting using	a tell us? s before 12 ⁺⁶ continuous of data captur rate is expected to vivaliability of access ce response times. 1 stillbirth and 2 new recorded in Februar ne NSHEI Re: Use of on the 15 th Februar nded. They still indicate not in the contessame logic has also all delivery charts. the Robson criterials and in this section.	re for this met vary dependar s to the birth conatal deaths ary. caesarean se ry, the c-section cate where valued ext of "improving been applied	ric is being nt on maternal s but no ction rates data on SPC charts alues are special ement" or to the vaginal	 Further train Awaiting bar Further recru Refining Birtl Appointed 2 Service Impressible SIP KPIs dem What are we do Large scale reservice impressible Preparing up Further mide Awaiting Birt 	actice in the boing for acuity and ing outcome with ment into cubrate Plus with new band 7s Dovement Plan ronstrate impro	pp comple for special rrent vacal national to S coordina emains pa evement in o new special en evidence ent event proceres	eted – data ist roles ncies B5 & eam etors used due t all except cialist/ lead e for return planned	quality im B6 o pandemi PDR rate dership role n to NHSEI	es to suppo	·	
Current Assurance Level: 5 (Feb-22)				 When expected to move to next level of assurance: Completion of work outlined in service improvement plan No midwifery vacancies No medical staffing vacancies 								


SRO: Paula Gardner (CNO)



Month 11 [February] | 2021-22 Maternity Summary

Worcestershire
Acute Hospitals
NHS Trust

Responsible Director: Chief Nursing Officer | Validated for Feb-22 as 14th March 2022






Month 11 [February] | 2021-22 Maternity Summary

Worcestershire Acute Hospitals NHS Trust

Responsible Director: Chief Nursing Officer | Validated for Feb-22 as 14th March 2022









Workforce



People and Culture Performance Report Month 11 - Headlines



People & Culture	Comments
Getting the basics right (appraisal, mandatory training, job plans)	 Mandatory training has dropped to 89% this month against a Model Hospital average of 88% Medical appraisal compliance has dropped to 90% but remains good compared to Model Hospital national average of 78% Non medical appraisal has improved to 80% compared with the national average of 78% Consultant Job Planning has increased by 3% to 79% this month which is 14% better than the same period last year. There is no longer a national average reported on Model Hospital.
Drivers of Bank & Agency spend	 Establishment has dropped by 34 wte due to removal of student nurses . Our vacancy rate of 8.19% is now on par with pre-covid average of 8.1% There are 167 staff on maternity leave compared to 145 for the same period last year Monthly sickness has reduced to 5.72% which is 1.17% higher than the same period last year. We are continuing to see higher rates of both Covid and non-Covid sickness absence during wave 4 of the pandemic. We have dropped to Quartile 3 (Poor) on Model Hospital for sickness as at November 2021. The annual turnover rate has increased again this month from 11.67% to 11.84%. This is 2.35% worse than the same period last year. Our monthly turnover has dropped this month which should start to show in the cumulative rate.
Staff Health & Wellbeing	 Cumulative sickness (rolling 12 months) has increased to 5.28% for the 12 month period which is 0.28% higher than last year We continue to have the one of the lowest cumulative sickness absence rates in the Region according to NHSEI Observatory data Sickness due to S10 (stress and anxiety) increased by 0.04% to 1.51%. 7 out of 8 divisions have higher levels of S10 than prepandemic rates with Estates and Facilities being an outlier. Wellbeing Conversations are continuing with training for Managers available on ESR. 95% of staff have had the first Covid vaccine, 93% have had their second vaccine and 81% have had their Booster. 63% of staff have had their Flu Vaccine The changes to VCOD regulations have led to the removal of access to NIMS data so will limit Trust's ability to obtain data.



Workforce Compliance Month 11 – (February 22): - What does the data tell us?



Appraisal and Medical Appraisal	Mandatory Training and Core Essential to Role Training	Consultant Job Planning	Annual Staff Turnover	Covid Risk Assessment Compliance
80% and 90%	89% and 88%	96%	11.84%	93%

What does the data tell us?

- **Appraisal** Non-medical appraisal rate has improved by 2% to 80% which is 4% higher than the same period last year. National average has dropped to 78% on Model Hospital so we are comparing well with other Trusts.
- Medical Appraisal Medical appraisal has dropped by 2% to 90% this month which is 9% higher than the same period last year.
- Mandatory Training Mandatory Training compliance has dropped by 1% to 89% this month which is the same as last year. National average has dropped to 88% so we are on par with other Trusts.
- Essential to Role Training Essential to Role training has improved by 1% to 88%.
- Consultant Job Plans Consultant job planning compliance has improved by 3% to 79% this month. This is 14% higher than the same period last year
- Staff Turnover Staff annual turnover has deteriorated by 0.17% this month to 11.84% which is 2.35% worse than the same period last year.
- Covid Risk Assessment Compliance Compliance has improved by 1% to 93% this month against a target of 100% by 31st March 2022.

National Benchmarking (February 2022)


Model Hospital National Benchmark for Mandatory Training compliance has dropped to 88% with our Trust recording 90% on Model Hospital (2020/21 rates). The national average for appraisals on Model Hospital has reduced to 78% (2020/21 rates) with our Trust recorded on Model Hospital at 79%. There is no longer a national benchmark for job planning.



Month 11 [February] 2021/22 Workforce "Getting the Basics Right" Summary



Responsible Director: Director of People and Culture | Validated for February 2022 as 12th March 2022





Workforce Performance Month 11 - What does the data tell us?



Substantive Vacancy Rate	Total Hours worked (including substantive bank and agency)	Monthly Sickness Absence Rate and cumulative sickness rate for 12 months	% Staff absent due to Stress and Anxiety (S10)	Number of staff off with Covid Sickness (S27) on the last Monday of month	Number of Staff self isolating due to Covid+ contact on the last Monday	Number of Staff on Maternity Leave	Bank and Agency Spend as a % of Gross Cost	Starters and Leavers in Month (NEW)
8.19%	6,462 wte	5.72% and 5.28%	1.51%	48	55	167	8.16% and 8.42%	100 starters; 94 leavers

What does the data tell us?

- Vacancy Rate Vacancy rates have improved by 087% this month to 8.19%. Our funded establishment has reduced this month by 34 wte. We have 77 wte more staff in post than last year.
- **Total Hours Worked** The total hours worked for substantive, bank and agency staff has reduced by 4 wte to 6,462 wte. Bank has reduced by 27 wte and agency has reduced by 2 wte. Total hours worked is 101 wte higher than the same period last year.
- **Monthly Sickness Absence Rate** Sickness has reduced by 0.46% to 5.72% which is 1.17% worse than the same period last year. Cumulative sickness for the 12 month period has increased to 5.28% from 5.21% which is 0.28% higher than the same period last year
- Absence due to Stress and Anxiety (S10) Absence due to stress and anxiety has increased by 0.04% to 1.51% this month which is 0.19% worse than last year
- Absence due to Covid Sickness (S27) 48 staff were absent due to Covid symptoms at the end of February compared to 47 at the end of January. This figure includes those staff who have reported sick due to effects of the Covid vaccine. Absence due to self isolation (including family symptoms and Test and Trace) reduced from 90 to 55 compared to our peak in mid July 2020 of 116.
- Maternity/Adoption Leave The number of staff on maternity and adoption leave has dropped by 11 this month to 167. This is still 22 more than the same period last year and will have an impact on wards with Specialty Medicine, SCSD and Urgent Care all having high numbers on maternity leave.
- Bank and Agency Spend as a % of Gross Cost this month has seen an reduction of 0.47% in bank spend compared to overall cost. However, Agency spend has increased by 0.6% this month to 8.41% of gross cost. Urgent Care remains an outlier for Agency spend with 25.12% of its gross spend (an increase of 4.6% from last month).
- **Starters and Leavers** Both starters and leavers are a worsened position from last month. We had 100 new starters compared to 118 last month. We had 94 leavers compared to 73 last month. February is impacted by a junior doctor rotation.

National Benchmarking (February 2022)


We dropped to Quartile 3 on Model Hospital for our monthly sickness with 5.8% compared to 5.6% national median (Nov 2021 data).



Month 11[February] 2021-22 Workforce "Drivers of Bank & Agency Spend" Summary



Responsible Director: Director of People and Culture | Validated for February -21 as 12th March 2022





Month 11 [February] 2021-22 "Drivers of Bank and Agency Spend" Summary (continued)



Responsible Director: Director of People and Culture | Validated for February -22 as 12th March 2022





Arrow depicts direction of travel since last month. Green is improved, Red is deteriorated and amber unchanged since last month.



Annual Plan Strategic Objectives: Workforce



		NHS Trus							
Strategic Wo	orkforce Plan	BAME Workforce	Organisational Development						
Introduce new roles and staffing models to support the delivery of our clinical services strategy Accelerate new ways of working from the Covid-19 experience		Undertake Covid-19 Risk Assessments for all BAME staff	Implement new operational management structure						
Annual Plan: Strategic Objectives Best people Ensure all our staff have annual appraisal and are suitably trained with up to date job plans. Ensure we have adequate staff to meet patient needs within financial envelope, and that this is a good place to work so that we can retain our substantive staff and reduce reliance on bank and agency staff.									

How have we been doing?

The following areas are where we perform below peer group average:

- Job Planning (>10% lower than pre-covid average)
- Vacancy rates for Medics (7% higher than national average)

Also of note is the increase in agency spend which is a result of:

- Continued higher levels of long term sickness absence
- 167 staff on maternity leave which although reducing is 22 more than the same period last year.
- Self isolation due to track and trace and family isolation
- Increased patient acuity and opening of surge areas
- Increase in annual leave being taken before the end of the leave year
- Thank you days

What improvements will we make?

- We will continue to work with divisions to ensure all staff are encouraged to take up the Covid and flu vaccines despite the changes to VCOD
- We will continue with the implementation of the Best People Programme to reduce our reliance on the temporary workforce
- We will continue our work to enhance the flexible working offer to staff including Location by Vocation
- We are working with Finance colleagues to improve visibility of establishment and vacancy information by uploading ADI data into ESR and HealthRoster.
- We are working with Corporate Nursing and NHSP colleagues to strengthen padlocks on HealthRoster to reduce spend.

Overarching Workforce Performance Level – 5 – February 2022 Previous Assurance Level - 5 – January 2022

To work towards improvement to next assurance level by June 2022

Ь.





Finance





H2 Plan

Our 2021/22 operational financial plan for H2 has been developed from a roll forward of the recurrent cost and non patient income actuals from H1 adjusting for workforce and activity trajectories, an assessment of additional PEP delivery in H2 and an assessment of any business cases which will start to impact in H2. The Trust's submitted H2 (October 2021 to March 2022) plan is a deficit of £(11.4)m before any additional ICS redistributions which lead to a full year (H1 actual + H2 plan) deficit of £(1.9)m.

Note that for External National Reporting purposes the Full Year Plan is based on the revised H1 submitted plan £1.1m surplus plus the H2 plan £(1.1)m deficit) - breakeven £0m.

Month 11 – February position

Against the M11 plan of £0.3m deficit we report a surplus of £0.5m, a favourable variance of £0.8m.

Against the H2 plan of £(0.8)m deficit, H2 to date at month 11 (February 2022) we report an actual deficit of £0.5m. Favourable H2 cumulative variance of £0.3m.

Income &
Expenditure
Overview

	Feb :	22 (Month	11)		H1			H2 to Date	H2 to Date			
Statement of Comprehensive Income	Plan	Actual	Var to Plan	Plan	Actual	Var to Plan	Plan	Actual	Varto Plan	Plan	Actual	Var to Plan
	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s
Operating Revenue & Income												
Operating income from patient care activities	44,379	46,793	2,414	267,840	271,670	3,830	223,037	233,064	10,027	490,877	504,734	13,857
Other operating income	4,185	2,817	(1,368)	11,586	13,415	1,829	19,651	12,091	(7,560)	31,237	25,506	(5,731)
Operating Expenses												
Employee expenses	(28,558)	(29,463)	(905)	(162,007)	(167,810)	(5,803)	(142,475)	(144,665)	(2,190)	(304,482)	(312,475)	(7,993)
Operating expenses excluding employee expenses	(18,726)	(17,320)	1,406	(106,844)	(108,175)	(1,331)	(92,938)	(92,302)	636	(199,782)	(200,477)	(695)
OPERATING SURPLUS / (DEFICIT)	1,280	2,827	1,547	10,575	9,100	(1,475)	7,275	8,187	912	17,850	17,287	(563)
Finance Costs												
Finance income	0	6	6	6	0	(6)	0	9	9	6	9	3
Finance expense	(1,009)	(1,068)	(59)	(6,148)	(6,147)	1	(5,059)	(5,301)	(242)	(11,207)	(11,448)	(241)
Movement in provisions	0	0	0	0	0	0	0	0	0	0	0	0
PDC dividends payable/refundable	(607)	(582)	25	(3,426)	(3,688)	(262)	(2,989)	(2,715)	274	(6,415)	(6,403)	12
Net Finance Costs	(1,616)	(1,644)	(28)	(9,568)	(9,835)	(267)	(8,048)	(8,008)	40	(17,616)	(17,843)	(227)
Other gains/(losses) including disposal of assets	0	(689)	(689)	1	19	18	0	(694)	(694)	1	(675)	(676)
SURPLUS/(DEFICIT) FOR THE PERIOD/YEAR	(336)	494	830	1,008	(716)	(1,724)	(773)	(515)	258	235	(1,231)	(1,466)
Less impact of Donated Asset Accounting (depreciation only)	1	10	9	48	(134)	(182)	5	72	67	53	(62)	(115)
Adjusted financial performance surplus/(deficit)	(335)	504	839	1,056	(850)	(1,906)	(768)	(443)	325	288	(1,293)	(1,581)
Less gains on disposal of assets	0	0	0	(1)	(19)	(18)	0	(15)	(15)	(1)	(34)	(33)
Adjusted financial performance surplus/(deficit) for the	(335)	504	839	1,055	(869)	(1,924)	(768)	(458)	310	287	(1,327)	(1,614)
purposes of system achievement	(333)	504	833	1,055	(603)	(1,524)	(768)	(456)	310	201	(1,327)	(1,514)

Combined Income in month variance £1.0m favourable — System Funding £0.2m (50% of the plan has been misallocated to expenditure with an neutral impact on the overall position), Education Income £0.3m, Other Income £0.7m (Including Improvement monies and International Nurses support), PCR Testing £0.1m, additional income adjustment in H2 plan (£0.2m) and postponement of Car Parking charging (£0.1m).

Employee expenses in month variance (£0.9)m adverse — Registered Nursing adverse variance of £0.9m Urgent Care has exceeded plan due to sickness and COVID as well as opening the Clinical Admissions Unit. SCSD has incurred additional costs to staff increased beds in Critical Care as well as increased cover for COVID and Sickness and additional theatre sessions. Specialty Medicine has had more new starters than forecast as well as increased COVID and redeployment cover.

Operating expenses in month variance (£1.4)m favourable — (including Non PbR) £1.4m favourable — are due to CNST premium Maternity Reduction received in M11 £0.8m, planning assumptions expecting higher PFI costs £0.3m, favourable depreciation £0.2m, business rebates £0.2m and some corrections to accruals within Digital £0.5m. These are being reduced by adverse variances from Independent Sector planning assumption (£0.4m), and Non PbR drugs higher than plan (£0.3m).

Financing Charges - asset verification resulting in a number of assets being written off c.£0.6m adverse.

I&E Delivery Assurance Level: Level 3

Reason: Risks remain over costs of delivering additional activity and the level of temporary staffing expenditure to deliver activity and deal with the current wave of COVID admissions in the Trust. Development of the 3 year plan into 2022/23 and beyond will be the key vehicle to improve assurance further. Timescales for 3 year plan underway. Divisions completed self assessment exercise in October and will form basis of plan to be taken to the Trust Board in March. **Assurance level reduced to level 3 pending confirmation of 22/23 final budget including robust productivity and efficiency programme.**





Trust Operational Plan

YTD In-month Normal Income Income Inc. Top Up/ Income Inc. Top Up/ Normal Income Generation Contracted COVID Payments COVID Payments Generation Contracted through PbR Variance £0.3m Variance £7.1m through PbR Plan Additional System funding £6.3 m Plan In-month Vaccinations/COVID tests £4.2m £473.6m £48.6m Additional System Funding £2.0m Gap Funded by additional Gap Funded by additional Elective Recovery Fund £3.0m Income £96.6m (20.4%) Income £11.0m (22.7%) Valor Inations /COVID tests 60.4 m CCG System Top Up and COVID £90.1m CCG System Top Up and COVID £8.9m Additional Payment to Additional Payment to Commissioner Block Levels Additional Payment to Commissioner Block Levels £12.4m Additional Payment to Commissioner Block Levels £12.4m (2.5%) Commissioner Block Levels £0.5m £0.5m (1.0%) Normal Income Generation Normal Income Generation Normal Income Generation Normal Income Generation Contracted through PbR Contracted through PbR Activity Contracted through PbR Contracted through PbR Activity and Other Income and Other Income Activity and Other Income Activity and Other Income £364.6m £364.6m (77.1%) £37.1m £37.1m (76.3%) £48 9m £37.6 m £480.6m £377.0m

Internal Operational Trust plan

Performance

Against

Original

Income


The Combined Income (including PbR pass-through drugs & devices and Other Operating Income) was £1.0m above the Trust's Operational Plan in February.

£9.8m additional System COVID/top up payment was received from Commissioners to cover additional costs of COVID and to fulfil the STP breakeven requirement (will continue until March 2022). Trust also can qualify for further funding should the STP achieve activity thresholds set by NHSE & I under the Elective Recovery Fund framework (ERF). In H1 the Trust has achieved is £3.0m EFR confirmed by the local System(STP) but no further monies are expected in H2. In addition to this the System has agreed to £10.3m funding to improve the financial performance of the Trust in H2 (£1.8m Elective Stretch and £8.5m Other System Support). This has been built into the H2 plan.

In month variance £1.0m: System Funding £0.2m (50% of the plan has been misallocated to expenditure with an neutral impact on the overall position), Education Income £0.3m, Other Income £0.7m (Including Improvement monies and International Nurses support), PCR Testing £0.1m, additional income adjustment in H2 plan (£0.2m) and postponement of Car Parking charging (£0.1m).







Performance
Against
Original
Internal
Operational
Trust plan

Expenditure

Above chart excludes Non PbR items. Month 12 adjusted to remove key one off items.

Total pay costs were £0.3m higher than month 10. Substantive pay spend was £24.6m (including additional sessions payments), an increase on £0.2m compared to last month driven by additional capacity costs £0.1 and back dated payments within SCSD of £0.1m due to increase in spine points for international recruits. These have been partially offset by no bank holidays and lower enhancements in February.

Total temporary staffing spend of £(4.9)m is an increase of £0.1m compared to last month and is the combined impact of normalising effect of the £0.2m Medics retrobenefit in M10 and the £0.1m Bank Nursing incentive payment paid in month 10.

Overall operating expenses excluding employee expenses (including Non PbR) was £17.3m in Month 11, a decrease of £0.9m compared with January, mainly due to:

- receipt of the CNST premium in month (£0.8m);
- a favourable movement on depreciation due to an asset verification exercise being completed in month which has resulted in a number of assets being written off from our asset register (£0.2m); and
- A backdated business rates rebate (£0.2m)

Partially offset by increases of :


- £0.3m in Supplies & Services (comprising the net effects of £0.2m increase in CDH costs, £0.2m normalising effect of activity impact accrued in M9, £0.1m increase 4ward Improvement costs offset by Income, £0.1m normalising effect following accruals corrected in M10 and £0.1m increase in catering provision partially offset by £0.5m benefit following correction to Digital accruals.
- £0.1m for international nurse recruitment.








Expenditure



As a result of Covid in H1 we saw our underlying temporary costs increase, this was reflected in our H2 submitted plan. However, the impact of Covid in H2 has exceeded plan. Weekly figures for March indicate we remain at a consistently high level of spend on temporary staffing and given the current high level of absenteeism and Covid patient numbers we expect this to continue for the remainder of March and into the new financial year.

Operating Expenses







Capital

Full year capital plan value is £53.6m while latest forecast is £52.0m including orders yet to be committed of £9.8m Risk adjusted forecast out-turn (RAFOT) after speaking with workstream leads and reviewing planned spend for Month 12 on a line by line basis is £47.5m. Year to date capital spend at Month 11 including PFI/IFRIC 12, invoiced values and work in progress (WIP) is £29.6m. This is an increase of £5.7m since month 10. We have commitments/outstanding purchase orders placed at a value of £12.5m where work should be completed or equipment received before the end of the financial year. The Capital Plan for 2022/23 is currently being finalised to confirm priorities for internally and externally funded schemes, and to enable the trust to deliver within the resources available. Following further work with work stream leads, the revised plan of 2022/23 shows the plan to be affordable with an increase to internal depreciation and external PDC requirements.

Capital Assurance Level:


Reason: Major capital schemes continue into 2022/23 requiring significant programme management. Commitment monitoring and prioritisation of schemes completed. Risk remains in medium term. Level 4 pending on going review of delivery to plan combined with compliance to expenditure plan by scheme with oversight at CPDG meetings and assessment of CRL to be postponed to next Financial Year (22/23)

Cash Balance

At the end of Feb 2022 the cash balance was £47.2m. The high cash balance is the result of the timing of receipts from the CCG's and NHSE under the COVID arrangement as well as the timing of supplier invoices.


Cash Assurance Level: Level 6

Reason: Good cash balances, rolling CF forecasting well established, achieving BPPC target, positive SPC trends on aged debtors and cash. Risks remain around sustainability given evolving regime for H2 2021/22 and beyond.



Productivity & Efficiency


The P&E Programme has delivered £4.78m of actuals at Month 11 against a plan of £4.20m, and the forecast remains favourable against plan for the M12 position.



Adjusted Expenditure Productivity Trend:

COVID significantly impacts our spend against weighted activity. This local metric allows us to follow productivity changes through COVID recovery and to track against forecasted activity going forward

February Cost per WAU is slightly increased due to levels of activity reduced on January. It will only improve if there is scope to increase activity, reduce costs significantly.








Appendices



Statistical Process Charts (SPC) Guidance





Orange dots signify a statistical cause for concern. A data point will highlight orange if it:

- A) Breaches the lower warning limit (special cause variation) when low reflects underperformance or breaches the upper control limit when high reflects underperformance.
- B) Runs for 7 consecutive points below the average when low reflects underperformance or runs for 7 consecutive points above the average when high reflects underperformance.
- C) Runs in a descending or ascending pattern for 7 consecutive points depending on what direction reflects a deteriorating trend.

Blue dots signify a statistical improvement. A data point will highlight blue if it:

- A) Breaches the upper warning limit (special cause variation) when high reflects good performance or breaches the lower warning limit when low reflects good performance.
- B) Runs for 7 consecutive points above the average when high reflects good performance or runs for 7 consecutive points below the average when low reflects good performance.
- C) Runs in an ascending or descending pattern for 7 consecutive points depending on what direction reflects an improving trend.

Special cause variation is unlikely to have happened by chance and is usually the result of a process change. If a process change has happened, after a period, warning limits can be recalculated and a step change will be observed. A process change can be identified by a consistent and consecutive pattern of orange or blue dots.



Levels of Assurance



RAG Rating	ACTIONS	OUTCOMES
	Comprehensive actions identified and agreed upon to	Evidence of delivery of the majority or all the agreed actions,
Level 7	address specific performance concerns AND recognition of	with clear evidence of the achievement of desired outcomes
	systemic causes/ reasons for performance variation.	over defined period of time i.e. 3 months.
	Comprehensive actions identified and agreed upon to	Evidence of delivery of the majority or all of the agreed
Level 6	address specific performance concerns AND recognition of	actions, with clear evidence of the achievement of the
	systemic causes/ reasons for performance variation.	desired outcomes.
	Comprehensive actions identified and agreed upon to	Evidence of delivery of the majority or all of the agreed
Level 5	address specific performance concerns AND recognition of	actions, with little or no evidence of the achievement of the
	systemic causes/ reasons for performance variation.	desired outcomes.
	Comprehensive actions identified and agreed upon to	Evidence of a number of agreed actions being delivered, with
Level 4	address specific performance concerns AND recognition of	little or no evidence of the achievement of the desired
	systemic causes/ reasons for performance variation.	outcomes.
	Comprehensive actions identified and agreed upon to	Some measurable impact evident from actions initially taken
Level 3	address specific performance concerns AND recognition of	AND an emerging clarity of outcomes sought to determine
	systemic causes/ reasons for performance variation.	sustainability, agreed measures to evidence improvement.
Level 2	Comprehensive actions identified and agreed upon to	Some measurable impact evident from actions initially taken.
Level 2	address specific performance concerns.	Some measurable impact evident from actions initially taken.
Level 1	Initial actions agreed upon, these focused upon directly	Outcomes sought being defined. No improvements yet
Level 1	addressing specific performance concerns.	evident.
Level 0	Emerging actions not yet agreed with all relevant parties.	No improvements evident.



FEBRUARY 2022 IN NUMBERS





7,033

Walk-in patients (A&E)



3,963

Patients arriving by ambulance



11,047

Inpatients



30,193

Face to Face outpatients



10,643

Telephone consultations



372

Babies



1,338

Elective operations



185

Trauma Operations



222

Emergency Operations



6.1

Average length of stay



176,078

Diagnostics

Page 124 of 183